phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha
RGD ID:
1310389
Description:
Predicted to enable clathrin binding activity and phosphatidylinositol kinase activity. Predicted to be involved in several processes, including phosphatidylinositol 3-kinase/protein kinase B signal transduction; phosphatidylinositol-3-phosphate biosynthetic process; and positive regulation of cell migration involved in sprouting angiogenesis. Predicted to act upstream of or within autophagosome organization; cellular response to starvation; and negative regulation of zinc ion transmembrane transport. Predicted to be located in several cellular components, including clathrin-coated vesicle; nucleoplasm; and trans-Golgi network. Predicted to be part of phosphatidylinositol 3-kinase complex. Predicted to be active in cytoplasm and plasma membrane. Orthologous to human PIK3C2A (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha); PARTICIPATES IN phosphoinositide metabolic pathway; inositol phosphate metabolic pathway; phosphatidylinositol 3-kinase signaling pathway; INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; bisphenol A; DDT.
[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PIK3C2A mRNA, AHR protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PIK3C2A mRNA]
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA more ...
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3C2A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA more ...
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA
[perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of PIK3C2A mRNA, [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of PIK3C2A mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3C2A mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIK3C2A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA